{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-015851","form_type":"8-K","ticker":"ITRMF","cik":"0001659323","company_name":"Iterum Therapeutics plc","filed_at":"2025-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.343207+00:00","generated_at":"2026-05-27T00:56:39.402147+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Iterum Therapeutics Q4 net loss $6.6M; cash $24.1M, ORLYNVAH approved","bullets":["Net loss Q4 2024 $6.6M vs $12.4M in Q4 2023; full year $24.8M vs $38.4M.","Cash and equivalents $24.1M at Dec 31, 2024; including $4.8M ATM proceeds Jan-Feb 2025, runway into H2 2025.","R&D expenses fell to $1.3M in Q4 2024 from $9.7M, driven by lower REASSURE trial costs.","ORLYNVAH (sulopenem etzadroxil/probenecid) approved by FDA for uUTIs in Q4 2024; pre-commercialization underway.","Repaid outstanding 6.500% Exchangeable Notes due 2025 in January 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-015851","json":"https://secwatch.observer/filing/0000950170-25-015851.json","markdown":"https://secwatch.observer/filing/0000950170-25-015851.md","text":"https://secwatch.observer/filing/0000950170-25-015851.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025015851/0000950170-25-015851-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659323/000095017025015851/itrm-20250207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T00:56:39.402147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}